One Capital Management LLC Purchases 3,741 Shares of Natera, Inc. $NTRA

One Capital Management LLC raised its position in Natera, Inc. (NASDAQ:NTRA) by 38.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 13,559 shares of the medical research company’s stock after purchasing an additional 3,741 shares during the period. One Capital Management LLC’s holdings in Natera were worth $3,106,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of NTRA. Norges Bank bought a new stake in Natera in the fourth quarter valued at approximately $372,398,000. JPMorgan Chase & Co. increased its stake in Natera by 9.4% in the third quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company’s stock valued at $1,871,914,000 after purchasing an additional 1,003,129 shares in the last quarter. Franklin Resources Inc. increased its stake in Natera by 37.5% in the third quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock valued at $428,987,000 after purchasing an additional 727,366 shares in the last quarter. AQR Capital Management LLC increased its stake in Natera by 39.0% in the third quarter. AQR Capital Management LLC now owns 2,400,065 shares of the medical research company’s stock valued at $386,338,000 after purchasing an additional 673,315 shares in the last quarter. Finally, Millennium Management LLC increased its stake in Natera by 215.7% in the third quarter. Millennium Management LLC now owns 527,942 shares of the medical research company’s stock valued at $84,983,000 after purchasing an additional 360,733 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.

Insider Activity at Natera

In related news, CFO Michael Burkes Brophy sold 482 shares of the stock in a transaction on Monday, May 4th. The shares were sold at an average price of $210.49, for a total transaction of $101,456.18. Following the completion of the transaction, the chief financial officer owned 57,496 shares in the company, valued at approximately $12,102,333.04. This represents a 0.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 1,438 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $202.84, for a total transaction of $291,683.92. Following the transaction, the insider owned 185,782 shares of the company’s stock, valued at $37,684,020.88. The trade was a 0.77% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 34,406 shares of company stock worth $6,984,955 over the last three months. 5.05% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on NTRA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research note on Tuesday, April 21st. Piper Sandler reissued an “overweight” rating and set a $249.00 price objective on shares of Natera in a research report on Tuesday, May 12th. Evercore reissued an “outperform” rating and set a $270.00 price objective on shares of Natera in a research report on Friday, May 8th. William Blair initiated coverage on shares of Natera in a research report on Tuesday, April 14th. They set an “outperform” rating for the company. Finally, BTIG Research lowered their price objective on shares of Natera from $260.00 to $250.00 and set a “buy” rating for the company in a research report on Monday, May 11th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Natera currently has an average rating of “Moderate Buy” and an average price target of $256.81.

Natera Stock Down 2.6%

Shares of NTRA stock opened at $213.05 on Wednesday. The firm has a fifty day moving average of $202.69 and a 200-day moving average of $215.84. Natera, Inc. has a 12-month low of $131.81 and a 12-month high of $256.36. The company has a market capitalization of $30.51 billion, a price-to-earnings ratio of -130.71 and a beta of 1.56.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.